Connect Biopharma initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Connect Biopharma with an Outperform rating and $8 price target. Connect Biopharma is a single-asset story built on rademikibart, a next-generation human IgG4 anti-interleukin-4 receptor alpha antibody that binds with higher affinity than dupilumab and, uniquely in the class, drives re